Management of tuberculosis

PREVIEW With the introduction of effective agents against tuberculosis (TB) and the use of combinations of these agents, significant progress has been made toward shortening the duration of therapy (ie, to 6 months) and reducing the relapse rate (ie, to >4%). In addition, use of directly observed therapy, in which patients receive prescribed medications under direct observation of healthcare personnel, has increased compliance and decreased the emergence of drug resistance. In this article, the authors review the principles and discuss the specifics of choosing, prescribing, and monitoring drug therapy for TB.

[1]  P. Winstanley,et al.  Clinically Significant Drug Interactions with Antituberculosis Agents , 1994, Drug safety.

[2]  L. Finelli,et al.  Initial drug regimens for the treatment of tuberculosis: evaluation of physician prescribing practices in New Jersey, 1994 to 1995. , 1998, Chest.

[3]  M. Pomerantz,et al.  Surgery in the treatment of multidrug-resistant tuberculosis. , 1997, Clinics in chest medicine.

[4]  D. Snider,et al.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.

[5]  T. Frieden,et al.  The use of legal action in New York City to ensure treatment of tuberculosis. , 1999, The New England journal of medicine.

[6]  S. Weis,et al.  The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. , 1994, The New England journal of medicine.

[7]  K. Miller,et al.  Tuberculosis in pregnancy: interactions, diagnosis, and management. , 1996, Clinical obstetrics and gynecology.

[8]  Miller Jm,et al.  Tuberculosis in pregnancy: interactions, diagnosis, and management. , 1996, Clinical obstetrics and gynecology.

[9]  J A Romeyn,et al.  Exogenous reinfection in tuberculosis. , 1970, The American review of respiratory disease.

[10]  W. Stead,et al.  Treatment of extrapulmonary tuberculosis. , 1989, Seminars in Respiratory Infections.

[11]  D. Dooley,et al.  Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  K. Castro,et al.  Trends in drug-resistant tuberculosis in the United States, 1993-1996. , 1997, JAMA.

[13]  H. Smith.  Paradoxical responses during the chemotherapy of tuberculosis. , 1987, The Journal of infection.

[14]  F. Drobniewski.  Multiple-drug-resistant tuberculosis , 2000, The Lancet.

[15]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[16]  S. A. Abdool Karim,et al.  Multidrug-resistant tuberculosis in patients without HIV infection. , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[17]  D. Cohn.  Treatment of multidrug-resistant tuberculosis. , 1995, The Journal of hospital infection.

[18]  V A Kazandjian,et al.  Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. , 1998, JAMA.

[19]  K. Stýblo,et al.  Recent advances in epidemiological research in tuberculosis. , 1982, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.